Published in World J Gastroenterol on September 28, 2015
Pre- and Post-Transplant Antiviral Therapy (HBV, HCV). Visc Med (2016) 0.75
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Liver transplantation (2). N Engl J Med (1989) 2.93
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 2.55
Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) (2010) 2.48
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol (2005) 2.19
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut (2000) 2.16
Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation (1996) 2.09
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology (1999) 1.86
Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut (2011) 1.78
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology (2000) 1.76
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol (2013) 1.73
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl (2005) 1.68
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant (2010) 1.67
Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology (1991) 1.65
Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol (1986) 1.63
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology (2003) 1.59
Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology (2002) 1.58
Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int (2008) 1.57
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol (2004) 1.55
Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology (2003) 1.53
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology (1998) 1.48
Costs and efficacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis (2008) 1.48
Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol (1992) 1.46
HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology (2003) 1.44
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology (2001) 1.29
Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl (2006) 1.29
Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology (2000) 1.24
Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet (1991) 1.20
Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol (2001) 1.20
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology (1996) 1.17
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl (2005) 1.10
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl (2007) 1.10
Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl (2005) 1.10
Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc (1987) 1.07
Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl (2005) 1.06
Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant (2010) 1.05
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl (2000) 1.05
Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl (2009) 1.05
Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology (1992) 1.04
High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant (2012) 1.02
Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl (2011) 1.01
Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol (1991) 0.97
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl (2013) 0.97
Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation (2000) 0.96
Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl (2007) 0.96
Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant (2003) 0.94
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology (2000) 0.94
Evolving strategies to prevent HBV recurrence. Liver Transpl (2004) 0.91
The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol (2012) 0.90
Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg (2001) 0.89
Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl (2007) 0.88
Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg (1998) 0.88
Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol (2005) 0.88
Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant (2006) 0.88
Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg (1999) 0.87
Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation (2004) 0.86
Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 0.86
Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation (2007) 0.86
Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl (2008) 0.86
De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther (2011) 0.86
Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation (2008) 0.85
Milestones and perspectives in viral hepatitis B. Liver Int (2011) 0.85
Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int (2009) 0.84
Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients. Liver Transpl (2014) 0.83
Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int (2008) 0.83
Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg (1999) 0.82
Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther (2004) 0.82
Liver transplantation for hepatitis B in the United States. Transplant Proc (2005) 0.82
Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. J Gastroenterol Hepatol (2014) 0.82
HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci (2010) 0.81
Hepatitis B vaccination after living donor liver transplantation. Liver Int (2007) 0.81
Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol (2010) 0.80
Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation (2000) 0.80
HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat (2005) 0.80
Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol (2013) 0.80
Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc (2006) 0.79
Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res (2008) 0.79
Should liver transplantation be performed for patients with hepatitis B? Transplantation (1994) 0.78
Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation (2001) 0.78
Hepatitis B in liver transplant recipients. Liver Transpl (2006) 0.77